We design developable antibodies using AI in under 6 weeks, wet-lab validated in 9 weeks, from your antigen sequence. No immunisation, no phage display, no animal.
Receive a feasibility study on your antigen - for freeAre you frustrated by the complexity and difficulty of generating precise antibodies against your targets?
Are you tired of time-consuming antibody discovery campaigns and betting on uncertain results?
Are you part of the many labs suffering from the lack of reproducibility?
If you answered yes to at least one of those questions, take a moment to read on to discover how EVOBodies™ can bring you more confidence.
Developability, before the antibody exists
CDR loop length
Hydrophobic surface
Positive charge
Negative charge
VH–VL charge
10 %20 %30 %31 %22 %Natural repertoirenaive B cells
Reached the clinic
CDR loops are the loops that grip the target; VH–VL charge is whether the two chains pull on each other. Natural repertoire: 500 antibodies, naive B cells of one healthy donor. Reached the clinic: 246 antibodies.
Share of antibodies outside the clinical envelope
The envelope is where the antibodies that reached the clinic sit: their 5th to 95th percentile on each measure. By construction, only 5 to 11 % of them fall outside it.
On CDR loop length (31 %) and Hydrophobic surface (22 %), the natural repertoire goes beyond it; on the other measures it does not.
We generate sequences inside that envelope, and we hold one variable low throughout: the charge on the face that grips your target. Across 239 clinical antibodies, the least charged fifth carries a developability flag 14 times less often than the most charged.
Measured on 239 clinical antibodies (GDPa1 v1.2, Ginkgo Datapoints, CC BY 4.0). Developability limits after TAP2 (Commun Biol 2024).
Sequences that leave the envelope are redesigned, not discovered in purification. And the charge on the face that grips your target tells you which wet-lab assay to run first.
| Assay | Least charged fifth | Most charged fifth |
|---|---|---|
| PR_Ova — polyréactivité | 0% | 25.6% |
| HAC — liaison à l'héparine | 0% | 26.1% |
| AC-SINS pH 7,4 | 2.1% | 29.8% |
| PR_CHO — polyréactivité | 2.8% | 20.5% |
| Metrics applied | Natural | Clinical |
|---|---|---|
| none | 100% | 100% |
| 1 — up to total CDR length | 68.8% | 91.1% |
| 2 — up to hydrophobic surface patches | 54.4% | 82.5% |
| 3 — up to positive charge patches | 53% | 78.5% |
| 4 — up to negative charge patches | 51% | 74% |
| 5 — up to VH/VL charge symmetry | 48.6% | 71.1% |
| Measure | Natural repertoire | Reached the clinic |
|---|---|---|
| CDR loop length (total CDR length) | 31.2% (156 of 500) | 8.9% (22 of 246) |
| Hydrophobic surface (hydrophobic surface patches) | 22% (110 of 500) | 10.6% (26 of 246) |
| Positive charge (positive charge patches) | 2.8% (14 of 500) | 5.3% (13 of 246) |
| Negative charge (negative charge patches) | 4.2% (21 of 500) | 5.3% (13 of 246) |
| VH–VL charge (VH/VL charge symmetry) | 3.6% (18 of 500) | 5.3% (13 of 246) |
Figure shown at its final state.
Let's design your antibody by de novo protein design, from your antigen sequence, with anticipated developability.
We design your antibody around an existing sequence for higher diversity, developability, or for jumping to freedom to operate informed by prior art.
Share the sequences with us and tell us what is your objective: we check developability, specificity, and improve yield and thermostability before you commit to scale-up.
Days (free)
2 weeks
3-4 weeks
up to 3 weeks
Engagement is progressive. You never commit to the next step before the previous one has been a success either for the generation, redesign or developability check.
Developability profile
Computed before synthesis
We start from a validated antibody, already screened for liabilities, and design the CDR loops that grip your target
Candidates designed by computation, produced and tested, with SPR measurements on IL-7Rα, PD-L1 and PMVK
Nanobody, antibody, miniprotein binder and peptide discovery, de novo design and humanization
Practical answers on de novo VHH design, patent freedom to operate, antibody formats and developability
Who we are: the team behind AI-designed antibodies and nanobodies, validated at the bench, from your antigen sequence
5 developability metrics, measured the same way on both sets
Ranked sequences with the epitope each engages, and a developability profile per candidate.
Each number in your report is attributable, so your team can check it.
Your sequences and your target data serve your project, and nothing else.
You keep all rights to the antibodies we design for you.
From your antigen to designed sequences.
To wet-lab validation of the candidates.
We design developable antibodies using AI in under 6 weeks, wet-lab validated in 9 weeks, from your antigen sequence. No immunisation, no phage display, no animal.
After our first discussion, we'll produce your free feasibility study in days, showing the confidence score for the next phases. Once you decide to move forward, you'll receive your designed antibody sequences after 6 weeks, wet-lab validated molecules from 9 weeks.
Antigen sequence is enough.
Every project starts with a free feasibility study, run before any commitment. We score your target from its 3D structure and tell you how much confidence we can have in generating antibodies against it. If that confidence is low, we say so plainly and we don't move forward, at no cost to you.
Immunochem was founded in 1998 and spent its first two decades supplying high-quality research antibodies, with a speciality on small molecules. Since 2023, the company focuses on antibody discovery and generation by computational design, backed by wet-lab validation.
Whatever the format (mAb, or single-domain antibody such as a nanobody or VHH), Immunochem delivers research-grade material and transfers the validated sequence and expression construct if appropriate. Gram-scale production runs with contract manufacturers.
The design work is computational and delivered digitally, so we serve customers worldwide from Belgium. Shipment of synthesised molecules follows standard research-reagent export rules, and no restriction applies in the European Union, the United Kingdom, Switzerland, the United States, India or China.
